Pliant Therapeutics Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For The Treatment Of ICI-Refractory Solid Tumors
Pliant Therapeutics receives FDA fast track designation for PLN-101095 in combination with pembrolizumab for the treatment of ICI-refractory solid tumors.
Pliant Therapeutics said PLN-101095 data from the Phase 1a/1b Fortify trial are expected in 2027.
Pliant Therapeutics Receives FDA Fast Track Designation For PLN-101095 In Combination With Pembrolizumab For The Treatment Of ICI-Refractory Solid Tumors - PLRX News | Rallies
PLRX•
